A digital health application designed to address the often overlooked emotional and psychosocial consequences of multiple sclerosis has shown significant benefits in a randomized controlled trial involving 470 people with the disease. The application, called levidex, was associated with improved disease-specific quality of life after six months when added to usual care, according to findings from the LAMONT study published in Multiple Sclerosis Journal – Experimental, Translational and Clinical. The results suggest that a fully automated, self-guided digital intervention may help fill a major gap in MS care, particularly for patients whose physical symptoms are accompanied by depression, sleep problems, reduced social participation, or difficulty adapting to life with a chronic neurological condition.
Multiple sclerosis is an inflammatory disease of the central nervous system in which the immune system damages myelin, the insulating layer surrounding nerve fibers, and sometimes the nerve fibers themselves. This disruption can interfere with communication between the brain, spinal cord, and the rest of the body, producing symptoms such as impaired mobility, sensory disturbances, fatigue, cognitive difficulties, pain, and visual problems. Modern disease-modifying therapies can reduce inflammatory activity and lower the risk of relapses or new lesions, but they do not directly resolve every consequence of living with MS. Many patients continue to experience what clinicians often call invisible symptoms, including anxiety, low mood, social isolation, uncertainty about the future, and difficulties maintaining employment or relationships.
The LAMONT trial specifically recruited people with MS who already had reduced disease-specific quality of life. Participants were assessed using the Hamburg Quality of Life Questionnaire for Multiple Sclerosis, or HAQUAMS, a validated instrument developed to measure the effects of MS across several domains. Unlike a general health survey, HAQUAMS is designed to capture disease-related changes in areas such as mobility, fatigue, mood, social functioning, and daily activities. The 470 participants were randomly assigned to receive either levidex in addition to treatment as usual, or treatment as usual alone. The primary outcome was the total HAQUAMS score six months after the intervention began.
The trial’s central finding was that participants who used levidex alongside usual care experienced a significantly greater improvement in MS-specific quality of life than those who received usual care alone. The researchers also reported that a clinically relevant improvement was achieved by significantly more people in the levidex group. This distinction is important: a statistically significant difference indicates that an observed effect is unlikely to be explained by chance, while a clinically relevant improvement suggests that the change was large enough to matter in everyday life. In chronic disease research, both dimensions are essential because even a reliable numerical change may have limited value if patients do not perceive a meaningful benefit.
The application was also associated with positive changes beyond the primary quality-of-life measure. Participants using levidex showed improvements in depressive symptoms, social and occupational functioning, and scores on MusiQoL, another instrument specifically developed to assess quality of life in multiple sclerosis. These findings are consistent with the therapeutic structure of the program, which combines elements of cognitive-behavioral therapy with mindfulness-based techniques. Cognitive-behavioral therapy aims to help users identify unhelpful patterns of thought and behavior and replace them with more adaptive responses. Mindfulness-based methods, meanwhile, train attention toward present-moment experiences and may help people respond differently to stress, uncomfortable sensations, and persistent worries.
Levidex is delivered through a web-based platform and does not require routine live interaction with a therapist. Its content is organized as a self-guided program presented in a conversational format, with modules covering coping with MS, emotional well-being, nutrition, physical activity, and sleep. Audio exercises and optional reminders are included to support regular use. This design reflects a growing area of digital therapeutics in which software delivers structured, evidence-based behavioral interventions rather than simply providing information. By removing the need to travel to appointments or coordinate frequent sessions, automated programs may be particularly useful for people living with fatigue, mobility limitations, geographic barriers, or long waiting lists for psychological care.
The study authors argue that the magnitude of the observed effects is notable because it was comparable to that reported for more resource-intensive psychosocial interventions. Dr. Björn Meyer, the study’s lead author and Head of Research at GAIA, said the automated nature of the program could allow it to reach more people with fewer barriers to entry. That scalability is potentially important in MS, where psychological and rehabilitation services are unevenly available and where specialist care often prioritizes relapses, medication management, and neurological monitoring. A digital intervention cannot replace individualized medical assessment, crisis support, or complex rehabilitation, but it may provide an additional layer of care between clinical appointments.
The researchers reported no serious adverse events and described user satisfaction as high. Nevertheless, the findings should be interpreted within the design and context of the trial. The study evaluated levidex as an addition to usual care, not as a replacement for disease-modifying treatment or specialist management. The application is intended to address quality of life and related behavioral and emotional challenges; it does not suppress the immune processes that drive MS or reverse neurological damage. As with other self-guided interventions, outcomes may also depend on whether participants engage consistently with the program. The available report does not provide detailed numerical results for every outcome in the supplied material, so the size of individual effects and the precise patterns of adherence require examination of the full publication.
The LAMONT study was conducted by researchers from GAIA in collaboration with the University of Duisburg-Essen, Neuromed Campus Hohenlind, NeuroTransData, the Vincera Clinics in Bad Waldsee, and the University Medical Center Hamburg-Eppendorf. The publication also discloses relevant potential conflicts of interest. Two authors are employees of GAIA AG, the trial sponsor and developer of levidex, while other authors reported professional relationships, funding, or honoraria connected to healthcare organizations and research activities. Such disclosures do not invalidate the results, but they are essential for readers assessing evidence for a company-developed digital therapeutic. Independent replication, longer follow-up, and comparisons with established psychological and rehabilitation programs will help determine how broadly the findings apply.
The results arrive as healthcare systems search for practical ways to support the full burden of chronic neurological disease. For people with MS, quality of life can deteriorate even when conventional measures such as relapse frequency or MRI lesion activity remain stable. A program that targets mood, coping, sleep, physical activity, and social functioning therefore addresses dimensions of health that may be invisible in a standard neurological examination but highly visible in daily life. The LAMONT trial indicates that levidex may offer a scalable tool for improving those outcomes in people whose quality of life has already been affected by MS. Its ultimate value will depend on sustained patient engagement, integration with professional care, and confirmation of its benefits in routine clinical settings and independent studies.
Subject of Research: People with multiple sclerosis
Article Title: Effectiveness of a digital health application (levidex) on quality of life in people with multiple sclerosis: A pragmatic, randomized controlled trial (LAMONT)
Web References: https://doi.org/10.1177/20552173261475519; German Federal Institute for Drugs and Medical Devices (BfArM) DiGA Directory, entry “levidex”
References: Meyer, B., Nelles, G., Betz, L., Bergmann, A., Jauch-Chara, K., Krause, N., Riemann, K., von Glasenapp, B., & Heesen, C. (2026). Effectiveness of a digital health application (levidex) on quality of life in people with multiple sclerosis: A pragmatic, randomized controlled trial (LAMONT). Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(3), 20552173261475519.
Keywords: Multiple sclerosis, levidex, digital therapeutics, digital health, quality of life, randomized controlled trial, LAMONT study, cognitive-behavioral therapy, mindfulness, invisible symptoms, depression, psychosocial care, MS rehabilitation
